nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP3A4—bone cancer	0.698	1	CbGaD
Nevirapine—CYP2B6—Cisplatin—bone cancer	0.0444	0.367	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—bone cancer	0.0298	0.246	CbGbCtD
Nevirapine—CYP2C9—Cisplatin—bone cancer	0.0235	0.194	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—bone cancer	0.0144	0.119	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—bone cancer	0.00915	0.0755	CbGbCtD
Nevirapine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00314	0.0569	CbGpPWpGaD
Nevirapine—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00217	0.0393	CbGpPWpGaD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00175	0.0317	CbGpPWpGaD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00171	0.031	CbGpPWpGaD
Nevirapine—Bullous eruption—Doxorubicin—bone cancer	0.00157	0.0125	CcSEcCtD
Nevirapine—Ulcerative stomatitis—Methotrexate—bone cancer	0.00155	0.0123	CcSEcCtD
Nevirapine—Liver injury—Cisplatin—bone cancer	0.00155	0.0123	CcSEcCtD
Nevirapine—Erythema nodosum—Epirubicin—bone cancer	0.00155	0.0123	CcSEcCtD
Nevirapine—Opportunistic infection—Doxorubicin—bone cancer	0.00154	0.0122	CcSEcCtD
Nevirapine—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00147	0.0267	CbGpPWpGaD
Nevirapine—Ulcerative stomatitis—Epirubicin—bone cancer	0.00145	0.0115	CcSEcCtD
Nevirapine—Erythema nodosum—Doxorubicin—bone cancer	0.00143	0.0114	CcSEcCtD
Nevirapine—Ulcer—Cisplatin—bone cancer	0.00138	0.011	CcSEcCtD
Nevirapine—Pain—Carboplatin—bone cancer	0.00136	0.0108	CcSEcCtD
Nevirapine—Ulcerative stomatitis—Doxorubicin—bone cancer	0.00134	0.0107	CcSEcCtD
Nevirapine—Hepatocellular injury—Cisplatin—bone cancer	0.0013	0.0104	CcSEcCtD
Nevirapine—Body temperature increased—Carboplatin—bone cancer	0.00125	0.00996	CcSEcCtD
Nevirapine—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00125	0.0227	CbGpPWpGaD
Nevirapine—Skin exfoliation—Cisplatin—bone cancer	0.00125	0.00989	CcSEcCtD
Nevirapine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00122	0.0222	CbGpPWpGaD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00122	0.0221	CbGpPWpGaD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00121	0.0219	CbGpPWpGaD
Nevirapine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00115	0.0209	CbGpPWpGaD
Nevirapine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00115	0.0209	CbGpPWpGaD
Nevirapine—Transaminases increased—Epirubicin—bone cancer	0.0011	0.00875	CcSEcCtD
Nevirapine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.0011	0.0199	CbGpPWpGaD
Nevirapine—Liver disorder—Methotrexate—bone cancer	0.00105	0.00834	CcSEcCtD
Nevirapine—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.00105	0.019	CbGpPWpGaD
Nevirapine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00103	0.0187	CbGpPWpGaD
Nevirapine—Transaminases increased—Doxorubicin—bone cancer	0.00102	0.00809	CcSEcCtD
Nevirapine—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00101	0.0183	CbGpPWpGaD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000945	0.0171	CbGpPWpGaD
Nevirapine—Blister—Epirubicin—bone cancer	0.000929	0.00738	CcSEcCtD
Nevirapine—Hepatotoxicity—Methotrexate—bone cancer	0.000927	0.00736	CcSEcCtD
Nevirapine—Face oedema—Cisplatin—bone cancer	0.000914	0.00726	CcSEcCtD
Nevirapine—Necrosis—Methotrexate—bone cancer	0.000912	0.00724	CcSEcCtD
Nevirapine—Rash erythematous—Epirubicin—bone cancer	0.000875	0.00695	CcSEcCtD
Nevirapine—Blister—Doxorubicin—bone cancer	0.00086	0.00683	CcSEcCtD
Nevirapine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00086	0.0156	CbGpPWpGaD
Nevirapine—Necrosis—Epirubicin—bone cancer	0.000853	0.00678	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000853	0.00677	CcSEcCtD
Nevirapine—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000844	0.0153	CbGpPWpGaD
Nevirapine—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.000827	0.015	CbGpPWpGaD
Nevirapine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000825	0.015	CbGpPWpGaD
Nevirapine—Rash erythematous—Doxorubicin—bone cancer	0.000809	0.00643	CcSEcCtD
Nevirapine—Pancreatitis—Cisplatin—bone cancer	0.000802	0.00637	CcSEcCtD
Nevirapine—Liver injury—Epirubicin—bone cancer	0.000796	0.00632	CcSEcCtD
Nevirapine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000795	0.0144	CbGpPWpGaD
Nevirapine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000793	0.0144	CbGpPWpGaD
Nevirapine—Bone disorder—Methotrexate—bone cancer	0.000792	0.0063	CcSEcCtD
Nevirapine—Necrosis—Doxorubicin—bone cancer	0.00079	0.00627	CcSEcCtD
Nevirapine—Ulcer—Methotrexate—bone cancer	0.000757	0.00601	CcSEcCtD
Nevirapine—Hepatic enzyme increased—Methotrexate—bone cancer	0.000757	0.00601	CcSEcCtD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000753	0.0137	CbGpPWpGaD
Nevirapine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000748	0.0136	CbGpPWpGaD
Nevirapine—Bone disorder—Epirubicin—bone cancer	0.000742	0.00589	CcSEcCtD
Nevirapine—Inflammation—Methotrexate—bone cancer	0.000738	0.00586	CcSEcCtD
Nevirapine—Liver injury—Doxorubicin—bone cancer	0.000737	0.00585	CcSEcCtD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000736	0.0134	CbGpPWpGaD
Nevirapine—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000718	0.013	CbGpPWpGaD
Nevirapine—Renal failure—Cisplatin—bone cancer	0.000717	0.0057	CcSEcCtD
Nevirapine—Neuropathy peripheral—Cisplatin—bone cancer	0.000715	0.00568	CcSEcCtD
Nevirapine—Conjunctivitis—Cisplatin—bone cancer	0.000709	0.00563	CcSEcCtD
Nevirapine—Ulcer—Epirubicin—bone cancer	0.000708	0.00563	CcSEcCtD
Nevirapine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000701	0.0127	CbGpPWpGaD
Nevirapine—Inflammation—Epirubicin—bone cancer	0.000691	0.00549	CcSEcCtD
Nevirapine—Hepatobiliary disease—Cisplatin—bone cancer	0.00069	0.00548	CcSEcCtD
Nevirapine—Bone disorder—Doxorubicin—bone cancer	0.000686	0.00545	CcSEcCtD
Nevirapine—Skin exfoliation—Methotrexate—bone cancer	0.000683	0.00543	CcSEcCtD
Nevirapine—Hepatocellular injury—Epirubicin—bone cancer	0.00067	0.00532	CcSEcCtD
Nevirapine—Ulcer—Doxorubicin—bone cancer	0.000655	0.00521	CcSEcCtD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000651	0.0118	CbGpPWpGaD
Nevirapine—Mouth ulceration—Methotrexate—bone cancer	0.000647	0.00514	CcSEcCtD
Nevirapine—Connective tissue disorder—Cisplatin—bone cancer	0.000644	0.00511	CcSEcCtD
Nevirapine—Skin exfoliation—Epirubicin—bone cancer	0.000639	0.00508	CcSEcCtD
Nevirapine—Inflammation—Doxorubicin—bone cancer	0.000639	0.00508	CcSEcCtD
Nevirapine—Hepatocellular injury—Doxorubicin—bone cancer	0.00062	0.00492	CcSEcCtD
Nevirapine—Lymphadenopathy—Methotrexate—bone cancer	0.000609	0.00484	CcSEcCtD
Nevirapine—Rash maculo-papular—Epirubicin—bone cancer	0.000609	0.00484	CcSEcCtD
Nevirapine—Mouth ulceration—Epirubicin—bone cancer	0.000606	0.00481	CcSEcCtD
Nevirapine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000594	0.0108	CbGpPWpGaD
Nevirapine—Skin exfoliation—Doxorubicin—bone cancer	0.000592	0.0047	CcSEcCtD
Nevirapine—Immune system disorder—Cisplatin—bone cancer	0.000592	0.0047	CcSEcCtD
Nevirapine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000587	0.0106	CbGpPWpGaD
Nevirapine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000582	0.0106	CbGpPWpGaD
Nevirapine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00058	0.0105	CbGpPWpGaD
Nevirapine—Hepatic failure—Methotrexate—bone cancer	0.000578	0.00459	CcSEcCtD
Nevirapine—Erythema—Cisplatin—bone cancer	0.00057	0.00453	CcSEcCtD
Nevirapine—Lymphadenopathy—Epirubicin—bone cancer	0.00057	0.00453	CcSEcCtD
Nevirapine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000566	0.0103	CbGpPWpGaD
Nevirapine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000564	0.0102	CbGpPWpGaD
Nevirapine—Rash maculo-papular—Doxorubicin—bone cancer	0.000563	0.00448	CcSEcCtD
Nevirapine—Mouth ulceration—Doxorubicin—bone cancer	0.00056	0.00445	CcSEcCtD
Nevirapine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000559	0.0101	CbGpPWpGaD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000556	0.0101	CbGpPWpGaD
Nevirapine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.000554	0.0101	CbGpPWpGaD
Nevirapine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000552	0.01	CbGpPWpGaD
Nevirapine—Dermatitis exfoliative—Methotrexate—bone cancer	0.000551	0.00437	CcSEcCtD
Nevirapine—Hepatic failure—Epirubicin—bone cancer	0.000541	0.0043	CcSEcCtD
Nevirapine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000541	0.00981	CbGpPWpGaD
Nevirapine—Ill-defined disorder—Cisplatin—bone cancer	0.000529	0.0042	CcSEcCtD
Nevirapine—Lymphadenopathy—Doxorubicin—bone cancer	0.000527	0.00419	CcSEcCtD
Nevirapine—Anaemia—Cisplatin—bone cancer	0.000527	0.00419	CcSEcCtD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000523	0.00949	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000519	0.00941	CbGpPWpGaD
Nevirapine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000518	0.0094	CbGpPWpGaD
Nevirapine—Dermatitis exfoliative—Epirubicin—bone cancer	0.000515	0.00409	CcSEcCtD
Nevirapine—Malaise—Cisplatin—bone cancer	0.000514	0.00409	CcSEcCtD
Nevirapine—Dermatitis bullous—Epirubicin—bone cancer	0.000509	0.00404	CcSEcCtD
Nevirapine—Hepatic failure—Doxorubicin—bone cancer	0.000501	0.00398	CcSEcCtD
Nevirapine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.0005	0.00907	CbGpPWpGaD
Nevirapine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000497	0.00902	CbGpPWpGaD
Nevirapine—Myalgia—Cisplatin—bone cancer	0.000485	0.00386	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000482	0.00383	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—bone cancer	0.00048	0.00381	CcSEcCtD
Nevirapine—Discomfort—Cisplatin—bone cancer	0.00048	0.00381	CcSEcCtD
Nevirapine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000478	0.00867	CbGpPWpGaD
Nevirapine—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000477	0.00379	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—bone cancer	0.000471	0.00374	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—bone cancer	0.000469	0.00373	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000468	0.00372	CcSEcCtD
Nevirapine—Anaphylactic shock—Cisplatin—bone cancer	0.000465	0.0037	CcSEcCtD
Nevirapine—Oedema—Cisplatin—bone cancer	0.000465	0.0037	CcSEcCtD
Nevirapine—Nervous system disorder—Cisplatin—bone cancer	0.000456	0.00363	CcSEcCtD
Nevirapine—Thrombocytopenia—Cisplatin—bone cancer	0.000456	0.00362	CcSEcCtD
Nevirapine—Skin disorder—Cisplatin—bone cancer	0.000452	0.00359	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—bone cancer	0.000449	0.00357	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—bone cancer	0.000445	0.00353	CcSEcCtD
Nevirapine—Anorexia—Cisplatin—bone cancer	0.000444	0.00352	CcSEcCtD
Nevirapine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000443	0.00804	CbGpPWpGaD
Nevirapine—Pancreatitis—Methotrexate—bone cancer	0.00044	0.0035	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000438	0.00348	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000438	0.00348	CcSEcCtD
Nevirapine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000434	0.00788	CbGpPWpGaD
Nevirapine—Face oedema—Doxorubicin—bone cancer	0.000434	0.00345	CcSEcCtD
Nevirapine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000429	0.00779	CbGpPWpGaD
Nevirapine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000429	0.00341	CcSEcCtD
Nevirapine—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000429	0.00778	CbGpPWpGaD
Nevirapine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000424	0.00337	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—bone cancer	0.00042	0.00334	CcSEcCtD
Nevirapine—Paraesthesia—Cisplatin—bone cancer	0.000418	0.00332	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—bone cancer	0.000416	0.00331	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—bone cancer	0.000415	0.0033	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—bone cancer	0.000412	0.00327	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000405	0.00322	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000405	0.00322	CcSEcCtD
Nevirapine—Decreased appetite—Cisplatin—bone cancer	0.000405	0.00321	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000402	0.00319	CcSEcCtD
Nevirapine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000399	0.00725	CbGpPWpGaD
Nevirapine—Pain—Cisplatin—bone cancer	0.000398	0.00316	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000397	0.00315	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000397	0.00315	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—bone cancer	0.000394	0.00313	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—bone cancer	0.000393	0.00312	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—bone cancer	0.000389	0.00309	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—bone cancer	0.000385	0.00306	CcSEcCtD
Nevirapine—Feeling abnormal—Cisplatin—bone cancer	0.000383	0.00305	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—bone cancer	0.000381	0.00303	CcSEcCtD
Nevirapine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00038	0.0069	CbGpPWpGaD
Nevirapine—Hyperglycaemia—Epirubicin—bone cancer	0.000379	0.00301	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—bone cancer	0.000379	0.00301	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—bone cancer	0.000374	0.00297	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000371	0.00295	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—bone cancer	0.000368	0.00293	CcSEcCtD
Nevirapine—Body temperature increased—Cisplatin—bone cancer	0.000368	0.00292	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—bone cancer	0.000367	0.00292	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—bone cancer	0.000365	0.0029	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—bone cancer	0.000364	0.00289	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—bone cancer	0.000364	0.00289	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—bone cancer	0.000359	0.00286	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—bone cancer	0.000354	0.00282	CcSEcCtD
Nevirapine—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000352	0.00639	CbGpPWpGaD
Nevirapine—Hyperglycaemia—Doxorubicin—bone cancer	0.000351	0.00279	CcSEcCtD
Nevirapine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000351	0.00636	CbGpPWpGaD
Nevirapine—Agranulocytosis—Epirubicin—bone cancer	0.00035	0.00278	CcSEcCtD
Nevirapine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000346	0.00628	CbGpPWpGaD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000344	0.00273	CcSEcCtD
Nevirapine—Hypersensitivity—Cisplatin—bone cancer	0.000343	0.00272	CcSEcCtD
Nevirapine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000343	0.00622	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000342	0.00621	CbGpPWpGaD
Nevirapine—Renal failure—Doxorubicin—bone cancer	0.000341	0.00271	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—bone cancer	0.00034	0.0027	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—bone cancer	0.00034	0.0027	CcSEcCtD
Nevirapine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000338	0.00613	CbGpPWpGaD
Nevirapine—Jaundice—Doxorubicin—bone cancer	0.000338	0.00268	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—bone cancer	0.000337	0.00268	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—bone cancer	0.000336	0.00267	CcSEcCtD
Nevirapine—Asthenia—Cisplatin—bone cancer	0.000334	0.00265	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—bone cancer	0.000331	0.00263	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000328	0.0026	CcSEcCtD
Nevirapine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000325	0.0059	CbGpPWpGaD
Nevirapine—Immune system disorder—Methotrexate—bone cancer	0.000325	0.00258	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—bone cancer	0.000324	0.00257	CcSEcCtD
Nevirapine—Diarrhoea—Cisplatin—bone cancer	0.000318	0.00253	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—bone cancer	0.000318	0.00253	CcSEcCtD
Nevirapine—Erythema—Methotrexate—bone cancer	0.000313	0.00249	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—bone cancer	0.000311	0.00247	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—bone cancer	0.000306	0.00243	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—bone cancer	0.000304	0.00241	CcSEcCtD
Nevirapine—Vomiting—Cisplatin—bone cancer	0.000296	0.00235	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—bone cancer	0.000294	0.00234	CcSEcCtD
Nevirapine—Rash—Cisplatin—bone cancer	0.000293	0.00233	CcSEcCtD
Nevirapine—Dermatitis—Cisplatin—bone cancer	0.000293	0.00233	CcSEcCtD
Nevirapine—Erythema—Epirubicin—bone cancer	0.000293	0.00233	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—bone cancer	0.00029	0.00231	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—bone cancer	0.000289	0.0023	CcSEcCtD
Nevirapine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000284	0.00516	CbGpPWpGaD
Nevirapine—Malaise—Methotrexate—bone cancer	0.000282	0.00224	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—bone cancer	0.000281	0.00223	CcSEcCtD
Nevirapine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00028	0.00509	CbGpPWpGaD
Nevirapine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000278	0.00504	CbGpPWpGaD
Nevirapine—Nausea—Cisplatin—bone cancer	0.000276	0.0022	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—bone cancer	0.000272	0.00216	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—bone cancer	0.000271	0.00215	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—bone cancer	0.000271	0.00215	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—bone cancer	0.000266	0.00212	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—bone cancer	0.000266	0.00212	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000265	0.0021	CcSEcCtD
Nevirapine—Malaise—Epirubicin—bone cancer	0.000264	0.0021	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—bone cancer	0.000263	0.00209	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—bone cancer	0.000255	0.00203	CcSEcCtD
Nevirapine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000255	0.00463	CbGpPWpGaD
Nevirapine—Ill-defined disorder—Doxorubicin—bone cancer	0.000251	0.002	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—bone cancer	0.00025	0.00199	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—bone cancer	0.00025	0.00199	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—bone cancer	0.00025	0.00199	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—bone cancer	0.000249	0.00198	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—bone cancer	0.000249	0.00198	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—bone cancer	0.000248	0.00197	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000248	0.00197	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—bone cancer	0.000246	0.00196	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—bone cancer	0.000244	0.00194	CcSEcCtD
Nevirapine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000244	0.00442	CbGpPWpGaD
Nevirapine—Anorexia—Methotrexate—bone cancer	0.000243	0.00193	CcSEcCtD
Nevirapine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000242	0.00438	CbGpPWpGaD
Nevirapine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00024	0.00436	CbGpPWpGaD
Nevirapine—Oedema—Epirubicin—bone cancer	0.000239	0.0019	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—bone cancer	0.000239	0.0019	CcSEcCtD
Nevirapine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000238	0.00432	CbGpPWpGaD
Nevirapine—Nervous system disorder—Epirubicin—bone cancer	0.000234	0.00186	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—bone cancer	0.000234	0.00186	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000233	0.00185	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—bone cancer	0.000232	0.00184	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—bone cancer	0.000231	0.00183	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—bone cancer	0.000231	0.00183	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—bone cancer	0.000229	0.00182	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000229	0.00182	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—bone cancer	0.000228	0.00181	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—bone cancer	0.000228	0.00181	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—bone cancer	0.000227	0.0018	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—bone cancer	0.000222	0.00176	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—bone cancer	0.000221	0.00176	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—bone cancer	0.000221	0.00176	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00022	0.00175	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—bone cancer	0.00022	0.00175	CcSEcCtD
Nevirapine—Pain—Methotrexate—bone cancer	0.000218	0.00173	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000218	0.00173	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—bone cancer	0.000217	0.00172	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—bone cancer	0.000216	0.00172	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—bone cancer	0.000215	0.00171	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—bone cancer	0.000215	0.0017	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—bone cancer	0.000212	0.00169	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—bone cancer	0.000211	0.00167	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—bone cancer	0.00021	0.00167	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—bone cancer	0.000209	0.00166	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—bone cancer	0.000208	0.00165	CcSEcCtD
Nevirapine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000206	0.00374	CbGpPWpGaD
Nevirapine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000206	0.00164	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—bone cancer	0.000206	0.00164	CcSEcCtD
Nevirapine—Pain—Epirubicin—bone cancer	0.000204	0.00162	CcSEcCtD
Nevirapine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000204	0.0037	CbGpPWpGaD
Nevirapine—Urticaria—Methotrexate—bone cancer	0.000203	0.00161	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—bone cancer	0.000202	0.0016	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—bone cancer	0.000202	0.0016	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000201	0.0016	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—bone cancer	0.000199	0.00158	CcSEcCtD
Nevirapine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000197	0.00358	CbGpPWpGaD
Nevirapine—Feeling abnormal—Epirubicin—bone cancer	0.000197	0.00156	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—bone cancer	0.000197	0.00156	CcSEcCtD
Nevirapine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000196	0.00355	CbGpPWpGaD
Nevirapine—Gastrointestinal pain—Epirubicin—bone cancer	0.000195	0.00155	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—bone cancer	0.000192	0.00153	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000191	0.00152	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—bone cancer	0.000191	0.00151	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—bone cancer	0.00019	0.00151	CcSEcCtD
Nevirapine—Pain—Doxorubicin—bone cancer	0.000189	0.0015	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—bone cancer	0.000189	0.0015	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—bone cancer	0.000189	0.0015	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—bone cancer	0.000188	0.00149	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000187	0.00339	CbGpPWpGaD
Nevirapine—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000185	0.00335	CbGpPWpGaD
Nevirapine—Asthenia—Methotrexate—bone cancer	0.000183	0.00146	CcSEcCtD
Nevirapine—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000182	0.00331	CbGpPWpGaD
Nevirapine—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000182	0.00331	CbGpPWpGaD
Nevirapine—Feeling abnormal—Doxorubicin—bone cancer	0.000182	0.00145	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000181	0.00144	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—bone cancer	0.000181	0.00144	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—bone cancer	0.000176	0.0014	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—bone cancer	0.000176	0.0014	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—bone cancer	0.000175	0.00139	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—bone cancer	0.000175	0.00139	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—bone cancer	0.000175	0.00139	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—bone cancer	0.000171	0.00136	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—bone cancer	0.000169	0.00134	CcSEcCtD
Nevirapine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000167	0.00304	CbGpPWpGaD
Nevirapine—Diarrhoea—Epirubicin—bone cancer	0.000164	0.0013	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—bone cancer	0.000163	0.00129	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—bone cancer	0.000162	0.00129	CcSEcCtD
Nevirapine—Rash—Methotrexate—bone cancer	0.000161	0.00128	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—bone cancer	0.000161	0.00128	CcSEcCtD
Nevirapine—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.00016	0.0029	CbGpPWpGaD
Nevirapine—Headache—Methotrexate—bone cancer	0.00016	0.00127	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—bone cancer	0.000159	0.00126	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—bone cancer	0.000156	0.00124	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—bone cancer	0.000152	0.00121	CcSEcCtD
Nevirapine—Nausea—Methotrexate—bone cancer	0.000152	0.00121	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—bone cancer	0.000151	0.0012	CcSEcCtD
Nevirapine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000151	0.00274	CbGpPWpGaD
Nevirapine—Rash—Epirubicin—bone cancer	0.000151	0.0012	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—bone cancer	0.000151	0.0012	CcSEcCtD
Nevirapine—Headache—Epirubicin—bone cancer	0.00015	0.00119	CcSEcCtD
Nevirapine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000149	0.0027	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000148	0.00268	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000146	0.00264	CbGpPWpGaD
Nevirapine—Nausea—Epirubicin—bone cancer	0.000142	0.00113	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Nevirapine—Rash—Doxorubicin—bone cancer	0.000139	0.00111	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—bone cancer	0.000139	0.00111	CcSEcCtD
Nevirapine—Headache—Doxorubicin—bone cancer	0.000139	0.0011	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000138	0.0025	CbGpPWpGaD
Nevirapine—Nausea—Doxorubicin—bone cancer	0.000131	0.00104	CcSEcCtD
Nevirapine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.00013	0.00236	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000129	0.00234	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000127	0.00231	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000126	0.00229	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000124	0.00226	CbGpPWpGaD
Nevirapine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000124	0.00225	CbGpPWpGaD
Nevirapine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000117	0.00213	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000113	0.00205	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NDUFA12—bone cancer	0.000112	0.00203	CbGpPWpGaD
Nevirapine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000106	0.00192	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000105	0.0019	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000104	0.00189	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000103	0.00188	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000103	0.00186	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000102	0.00185	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NT5C3A—bone cancer	9.29e-05	0.00169	CbGpPWpGaD
Nevirapine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.05e-05	0.00164	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NDUFA12—bone cancer	9.05e-05	0.00164	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.97e-05	0.00163	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.89e-05	0.00161	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	8.89e-05	0.00161	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	8.85e-05	0.00161	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NDUFA12—bone cancer	8.84e-05	0.0016	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.77e-05	0.00159	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	8.76e-05	0.00159	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.02e-05	0.00145	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.02e-05	0.00145	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GSTP1—bone cancer	7.6e-05	0.00138	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NT5C3A—bone cancer	7.5e-05	0.00136	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	7.5e-05	0.00136	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NT5C3A—bone cancer	7.33e-05	0.00133	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NDUFA12—bone cancer	6.29e-05	0.00114	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NDUFA12—bone cancer	6.23e-05	0.00113	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.87e-05	0.00106	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.79e-05	0.00105	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NDUFA12—bone cancer	5.33e-05	0.000967	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NT5C3A—bone cancer	5.21e-05	0.000945	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NT5C3A—bone cancer	5.17e-05	0.000937	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NT5C3A—bone cancer	4.41e-05	0.000801	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NDUFA12—bone cancer	4.11e-05	0.000746	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ENO2—bone cancer	4.07e-05	0.000738	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—DHFR—bone cancer	3.78e-05	0.000685	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GNA11—bone cancer	3.53e-05	0.00064	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.41e-05	0.000618	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ENO2—bone cancer	3.28e-05	0.000596	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ENO2—bone cancer	3.21e-05	0.000582	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP3A4—bone cancer	3.2e-05	0.000581	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—DHFR—bone cancer	3.05e-05	0.000553	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—DHFR—bone cancer	2.98e-05	0.00054	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GNA11—bone cancer	2.85e-05	0.000517	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GNA11—bone cancer	2.78e-05	0.000505	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTP1—bone cancer	2.74e-05	0.000496	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP3A4—bone cancer	2.58e-05	0.000468	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.52e-05	0.000458	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ENO2—bone cancer	2.28e-05	0.000414	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ENO2—bone cancer	2.26e-05	0.000411	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTP1—bone cancer	2.21e-05	0.000401	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTP1—bone cancer	2.16e-05	0.000392	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—DHFR—bone cancer	2.12e-05	0.000384	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—DHFR—bone cancer	2.1e-05	0.000381	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GNA11—bone cancer	1.98e-05	0.000359	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GNA11—bone cancer	1.96e-05	0.000356	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ENO2—bone cancer	1.93e-05	0.000351	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.79e-05	0.000326	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—DHFR—bone cancer	1.79e-05	0.000325	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.78e-05	0.000323	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.77e-05	0.000321	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GNA11—bone cancer	1.68e-05	0.000304	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTP1—bone cancer	1.53e-05	0.000278	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTP1—bone cancer	1.52e-05	0.000276	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.52e-05	0.000276	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.51e-05	0.000274	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ENO2—bone cancer	1.49e-05	0.000271	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTGS2—bone cancer	1.42e-05	0.000257	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—DHFR—bone cancer	1.38e-05	0.000251	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTP1—bone cancer	1.3e-05	0.000236	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GNA11—bone cancer	1.29e-05	0.000235	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTGS2—bone cancer	1.14e-05	0.000208	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTGS2—bone cancer	1.12e-05	0.000203	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTP1—bone cancer	1e-05	0.000182	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTGS2—bone cancer	7.95e-06	0.000144	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTGS2—bone cancer	7.88e-06	0.000143	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTGS2—bone cancer	6.73e-06	0.000122	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTGS2—bone cancer	5.2e-06	9.43e-05	CbGpPWpGaD
